Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 5/20 | 0.43 |
| ▸ | SOAT1 | P35610 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 9/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | LIPC | P11150 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 2/20 | 0.36 |
| ▸ | PPARA | Q07869 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3577349 | 1.00 | DGAT1 (0.43) | DGAT1SOAT1FFAR4KCNH2PTGDR2 | |
| SCHEMBL3033676 | 0.88 | CCRL2 (0.41) | DGAT1SOAT1FFAR4PTGDR2 | |
| SCHEMBL3033678 | 0.88 | CCRL2 (0.41) | DGAT1SOAT1FFAR4PTGDR2 | |
| SCHEMBL3046479 | 0.88 | CSNK1D (0.36) | — | |
| SCHEMBL3576693 | 0.85 | FFAR4 (0.48) | DGAT1SOAT1FFAR4KCNH2PTGDR2 | |
| SCHEMBL3576690 | 0.85 | FFAR4 (0.48) | DGAT1SOAT1FFAR4KCNH2PTGDR2 | |
| SCHEMBL1587823 | 0.83 | CNR2 (0.43) | CYP3A4 | |
| SCHEMBL3044441 | 0.78 | CSNK1D (0.39) | — | |
| SCHEMBL14999612 | 0.76 | CETP (0.37) | DGAT1SOAT1FFAR4KCNH2PTGDR2 | |
| SCHEMBL3036495 | 0.74 | GRIA2 (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1973889-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| US-7781426-B2 | cholesterol ester transfer protein (CETP) inhibitors such as (4S,5R)-5-[3,5-bis(trifluoromethyl)phenyl]-3-[2-(3,3-dimethylpiperidin-1-yl)-5-(trifluoromethyl)benzyl]-4-methyl-1,3-oxazolidin-2-one, useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis | MERCK SHARP & DOHME CORP. (US) | 2010-08-24 | — | — | US | disclosed |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | KOWA COMPANY, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090075979-A1 | CETP Inhibitors | MERCK SHARP & DOHME LLC | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075979-A1 | CETP Inhibitors | CETP, APOB, MTTP | DGAT1 171/4885SOAT1 23/4885FFAR4 785/4885 |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | CETP, NPC1L1, MTTP | DGAT1 178/4885SOAT1 32/4885FFAR4 991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.